CA3147752A1 - Methods of treating sleep disorders associated with pain - Google Patents

Methods of treating sleep disorders associated with pain Download PDF

Info

Publication number
CA3147752A1
CA3147752A1 CA3147752A CA3147752A CA3147752A1 CA 3147752 A1 CA3147752 A1 CA 3147752A1 CA 3147752 A CA3147752 A CA 3147752A CA 3147752 A CA3147752 A CA 3147752A CA 3147752 A1 CA3147752 A1 CA 3147752A1
Authority
CA
Canada
Prior art keywords
pain
fmsd
sleep
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3147752A
Other languages
English (en)
French (fr)
Inventor
Paul BLAHUNKA
Gerard MAREK
Katherine TRACY
Mary Beth BLAUWET
Michael Smith
Mark WALZER
Marci ENGLISH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Global Development Inc
Original Assignee
Astellas Pharma Global Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Global Development Inc filed Critical Astellas Pharma Global Development Inc
Publication of CA3147752A1 publication Critical patent/CA3147752A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3147752A 2019-07-23 2020-07-22 Methods of treating sleep disorders associated with pain Pending CA3147752A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962877573P 2019-07-23 2019-07-23
US62/877,573 2019-07-23
PCT/US2020/043047 WO2021016338A1 (en) 2019-07-23 2020-07-22 Methods of treating sleep disorders associated with pain

Publications (1)

Publication Number Publication Date
CA3147752A1 true CA3147752A1 (en) 2021-01-28

Family

ID=72047043

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3147752A Pending CA3147752A1 (en) 2019-07-23 2020-07-22 Methods of treating sleep disorders associated with pain

Country Status (10)

Country Link
US (1) US20220370468A1 (https=)
EP (1) EP4003357A1 (https=)
JP (1) JP2022541634A (https=)
KR (1) KR20220038344A (https=)
CN (1) CN114144183A (https=)
AU (1) AU2020318996A1 (https=)
BR (1) BR112022001056A2 (https=)
CA (1) CA3147752A1 (https=)
MX (1) MX2022000892A (https=)
WO (1) WO2021016338A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320637D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
MX350745B (es) * 2009-11-06 2017-09-14 Sk Biopharmaceuticals Co Ltd * El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
SG11201509989VA (en) * 2013-06-06 2016-01-28 Astellas Pharma Inc Benzothiophene compound

Also Published As

Publication number Publication date
KR20220038344A (ko) 2022-03-28
BR112022001056A2 (pt) 2022-05-24
JP2022541634A (ja) 2022-09-26
MX2022000892A (es) 2022-03-11
AU2020318996A1 (en) 2022-02-03
CN114144183A (zh) 2022-03-04
EP4003357A1 (en) 2022-06-01
WO2021016338A1 (en) 2021-01-28
US20220370468A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
Myles et al. Benefits and risks of dexamethasone in noncardiac surgery
McKeown Pain management issues for the geriatric surgical patient
Backonja et al. Pharmacologic management part 1: better-studied neuropathic pain diseases
Jongen et al. Neuropathic pain and pharmacological treatment
US20250177378A1 (en) Treatment of depression
WO2016062285A1 (zh) 神经系统疾病用药在制备抗癌医药组合物中的应用
JP2026050474A (ja) Ｎｍｄａ拮抗薬の副作用の低減
CA3083341C (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
Morón Merchante et al. Tramadol/Paracetamol Fixed‐Dose Combination for Chronic Pain Management in Family Practice: A Clinical Review
Hauer et al. Pediatric pain and symptom management guidelines
Cope Cancer pain management considerations in older adults
TW202228666A (zh) 使用ghb之治療方法
US20220370468A1 (en) Methods of treating sleep disorders associated with pain
Gleeson Symptom control in palliative care
Zheng et al. Tolerability of biphasic-release hydrocodone bitartrate/acetaminophen tablets (MNK-155): A phase III, multicenter, open-label study in patients with osteoarthritis or chronic low back pain
Schwenke et al. Tapentadol prolonged release as used in clinical practice in patients with severe chronic tumor pain
EP4541372A1 (en) Drug therapy for obsessive-compulsive disorder targeting dopamine d1 signal in striatal striosomes
US20220265666A1 (en) Methods of treating substance abuse disorder, dyspnea, tinnitus, and child and adolescent depression
Richards et al. (312/759): ALGRX 4975 reduces pain of acute lateral epicondylitis: Preliminary results from a randomized, double-blind, placebo-controlled, phase II multicenter clinical trial
Hemraj et al. Persistent Pain in the Older Adult: Practical Considerations for
Kapoor et al. Challenges in the management of cancer pain in elderly population: A review
ELsharkawy et al. Optimization of The Dose of Pregabalin as Pre-Anaesthetic Medication in Patients Undergoing Total Hip Arthroplasty Under Spinal Anaesthesia: Randomized Controlled Trial
Duraney Exparel Versus Bupivacaine: Outcomes, Advantages, And Costs
Singhal et al. Who is pushing patients to death trap by improper use of codeine? Time now to reorient physicians or ban the use of codeine!
Danami et al. Pain management and palliative care in the head and neck cancer setting

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240903

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260109

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260204